Alto Neuroscience, Inc.

NYSE:ANRO

Biotechnology

Healthcare
$25.91 +1.84%

+$0.40 today

Market cap
$1.04B
Beta
1.25
P/E (TTM)
-9.8
EPS (TTM)
-$2.26
52W Low $2.15High $28.44

Volume 0.99M

Average 0.34M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$51.77M

FY 2025 · Annual

Investing Cash Flow

-$24,000.00

FY 2025 · Annual

Financing Cash Flow

$60.08M

FY 2025 · Annual

-55.7% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(9.19M)(27.71M)(36.31M)(61.43M)(63.24M)
Depreciation & Amortization145K342K373K502K661K
Deferred Income Tax00000
Stock-Based Compensation227K1.76M2.89M7.63M8.11M
Change in Working Capital(572K)4.58M(698K)4.06M33K
Accounts Receivables(1.29M)1.16M325K00
Inventory00000
Accounts Payables458K1.01M(632K)516K221K
Other Working Capital255K2.42M(391K)3.54M(188K)
Other Non-Cash Items125K632K291K1.81M2.67M
Operating Cash Flow(9.26M)(20.39M)(33.45M)(47.42M)(51.77M)
Capital Expenditures(680K)(732K)(470K)(2.08M)(24K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(680K)(732K)(470K)(2.08M)(24K)
Debt Repayment09.83M01.25M9.48M
Common Stock Issued7K43K181K137.58M50.7M
Common Stock Repurchased0000(167K)
Dividends Paid00000
Other Financing Activities(205K)(341K)(2.05M)(3.14M)67K
Financing Cash Flow31.69M43.79M68.13M135.69M60.08M
Effect of Forex Changes(50K)(24K)(8K)(11K)(30K)
Net Change in Cash21.7M22.64M34.2M86.18M8.26M
Free Cash Flow(9.94M)(21.13M)(33.92M)(49.5M)(51.79M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$63.2M
+ D&A$661.0K
+ Stock-Based Comp$8.1M
+ Deferred Tax$0
+ Working Capital$33.0K
+ Other Non-Cash$2.7M
= Operating Cash Flow-$51.8M
- Capex-$24.0K
= Free Cash Flow-$51.8M

Analysis

FY2025 free cash flow is -$51.8M. FCF conversion is 81.9% of net income. Operating cash flow was -$51.8M, with capex of -$24.0K. The largest bridge item is Stock-Based Comp at $8.1M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 10, 2026
8-KCurrent reportNov 10, 2026
SC 13GSC 13G filingOct 30, 2026
4Statement of changes in beneficial ownershipOct 5, 2026
4Statement of changes in beneficial ownershipOct 1, 2026

Does ANRO generate free cash flow?

Alto Neuroscience, Inc. (ANRO) generated -$51.79M of free cash flow in fiscal 2025.

How much operating cash flow does ANRO produce?

Operating cash flow was -$51.77M, before capital expenditures of $24,000.00.